Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Want to see RAPP full AI Analyst Report?
Top Page
Rapport Therapeutics, Inc.
(NASDAQ:RAPP)
Select Model
Select Model
Rating:60Neutral
Price Target:
$40.00
▲(0.73% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance driven by persistent large losses and substantial cash burn, despite a strong, low-leverage balance sheet. Offsetting this, technicals show a solid uptrend and positive momentum, and the recent positive Phase 2a update is a meaningful catalyst. Valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Low leverage / strong balance sheet
Very low leverage and a rebuilt equity base give Rapport durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. This supports progressing RAP-219 into pivotal trials and reduces short-term solvency risk versus peers.
Negative Factors
High cash burn
Sustained negative operating and free cash flow at this scale requires ongoing external funding and increases dilution risk. Persistently high burn can constrain R&D prioritization and pace, making long-term program execution contingent on financing or milestone receipts.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low leverage and a rebuilt equity base give Rapport durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. This supports progressing RAP-219 into pivotal trials and reduces short-term solvency risk versus peers.
Read all positive factors
Rapport Therapeutics, Inc. (RAPP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.80B
Dividend YieldN/A
Average Volume (3M)358.80K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue GrowthN/A
EPS Growth-18.14%
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.60
Shares Outstanding47,826,927
10 Day Avg. Volume292,794
30 Day Avg. Volume358,799
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue65.47
Enterprise Value/Gross Profit67.12
Enterprise Value/Ebitda-11.08
Forecast
1Y Price Target
$53.75Price Target Upside35.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.36
Revenue Forecast (FY)$20.00M
Rapport Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its l...
How the Company Makes Money
null...
Rapport Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 19.51M | 0.00 | -839.00K | -112.00K | -15.00K |
| EBITDA | -118.14M | -124.08M | -77.47M | -34.66M | -10.35M |
| Net Income | -107.28M | -111.48M | -78.31M | -34.79M | -10.65M |
Balance Sheet | |||||
| Total Assets | 497.60M | 512.43M | 314.93M | 155.42M | 31.60M |
| Cash, Cash Equivalents and Short-Term Investments | 476.78M | 490.54M | 305.28M | 147.48M | 31.16M |
| Total Debt | 10.80M | 11.48M | 1.48M | 2.15M | 10.44M |
| Total Liabilities | 26.09M | 27.78M | 9.51M | 181.06M | 12.10M |
| Stockholders Equity | 471.51M | 484.65M | 305.43M | -25.63M | 19.50M |
Cash Flow | |||||
| Free Cash Flow | -80.54M | -88.09M | -67.23M | -28.82M | -3.53M |
| Operating Cash Flow | -80.30M | -87.47M | -64.83M | -27.18M | -3.24M |
| Investing Cash Flow | -170.56M | -187.47M | -170.14M | -78.86M | -5.28M |
| Financing Cash Flow | 271.31M | 270.79M | 221.63M | 145.14M | 39.69M |
Rapport Therapeutics, Inc. Technical Analysis
Positive
39.71
Price Trends
33.85
Positive
31.04
Positive
27.91
Positive
Market Momentum
0.63
Positive
56.82
Neutral
46.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPP, the sentiment is Positive. The current price of 39.71 is above the 20-day moving average (MA) of 36.19, above the 50-day MA of 33.85, and above the 200-day MA of 27.91, indicating a bullish trend. The MACD of 0.63 indicates Positive momentum. The RSI at 56.82 is Neutral, neither overbought nor oversold. The STOCH value of 46.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAPP.
Rapport Therapeutics, Inc. Risk Analysis
Rapport Therapeutics, Inc. disclosed 87 risk factors in its most recent earnings report. Rapport Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rapport Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $1.66B | 2.32 | 47.59% | ― | 13.25% | ― | |
60 Neutral | $1.80B | -18.61 | -24.79% | ― | ― | -18.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.53B | -26.05 | -21.04% | ― | ― | 13.79% | |
47 Neutral | $236.73M | -1.73 | -46.82% | ― | ― | -103.37% |
* Healthcare Sector Average
RAPP
Rapport Therapeutics, Inc.
37.72
27.68
275.70%
INVA
Innoviva
22.46
3.49
18.40%
ELVN
Enliven Therapeutics
41.54
25.55
159.79%
LENZ
LENZ Therapeutics
7.55
-21.85
-74.32%
Rapport Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
Positive
Apr 21, 2026
On April 21, 2026, Rapport Therapeutics reported follow-up data from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, showing sustained and in some cases improved seizure control after dosing stopped. In weeks 9–12, pati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.